Business Context and Reporting Period
Company: Apollomics Inc.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: August 2026 (Filed August 11, 2026)
Principal Office: Foster City, California
The filing reports the entry into material definitive agreements regarding a private placement of equity securities and related party transactions.
Key Financial Metrics and Transaction Details
This filing details a capital raise rather than periodic financial performance metrics (revenue, profit, cash flow). Key transaction figures include:
- Total Shares Issued: Up to 700,001 Class A Ordinary Shares.
- Cash Proceeds: $8,000,010.00 from the sale of 533,334 shares at $15.00 per share.
- Debt Conversion: $2,000,000.00 principal of an unsecured Convertible Promissory Note converted into 166,667 shares at $12.00 per share.
- Use of Proceeds: Clinical development, working capital, and general corporate purposes.
- Transaction Costs: No placement agents, underwriters, or finder's fees were utilized.
Material Changes and Related Party Transactions
The filing discloses significant related party transactions involving executive officers and directors:
- Mr. Hung-Wen (Howard) Chen (CEO/Chairman): Subscribed for 370,000 shares total (103,333 via cash at $15.00/share; 166,667 via note conversion at $12.00/share).
- Mr. Peter Kuan-How Lin (CFO): Subscribed for 26,667 shares for $400,005.00.
- Maxpro Investment Co., Ltd. (Affiliate of COO/Director Alex Chen): Subscribed for 20,000 shares for $300,000.00.
- Unaffiliated Investors: Purchased the remaining 283,344 cash subscription shares.
The Audit Committee reviewed and recommended these transactions, and the Board approved them with interested directors abstaining from voting.
Guidance, Outlook, and Risks
Outlook: The Company intends to utilize net cash proceeds to advance clinical development and support working capital needs.
Risks and Contingencies:
- Registration Exemption: Securities were sold under Section 4(a)(2) of the Securities Act and/or Rule 506 of Regulation D. They are not registered and may not be offered or sold in the U.S. absent registration or an applicable exemption.
- Closing Conditions: The Private Placement is expected to close on or about August 14, 2026, subject to customary closing conditions.
Investor Verification Checklist
- Verify the closing of the Private Placement on or about August 14, 2026.
- Confirm the conversion of the $2,000,000 Convertible Promissory Note held by the CEO.
- Review the impact of the 700,001 new shares on existing shareholder dilution.
- Monitor future filings for the utilization of the $8,000,010 cash proceeds in clinical development.
- Check for any subsequent filings regarding the registration status of the issued securities.